April 14, 2022
1 min read
Study results showed that women with breast cancer had a greater risk for CVD events, including heart failure and cardiomyopathy, than women without breast cancer.
The study also reported higher rates of CVD-related mortality and all-cause mortality in the breast cancer cohort. It was the top story in hematology/oncology last week.
The second top story covered an announcement from the National Cancer Institute (NCI) that its director, Norman E. “Ned” Sharpless, MD, will step down from the position after nearly 5 years.
Read these and more top stories in hematology/oncology below:
Women with breast cancer at higher risk for cardiovascular disease events, mortality
Women with breast cancer exhibited a higher risk for heart failure, cardiomyopathy and other disease events than women without cardiovascular breast cancer, according to prospective study results published in Journal of Clinical Oncology. Read more.
Sharpless to step down as National Cancer Institute director
NCI Director Sharpless will leave his position on April 29, after which NCI Principal Deputy Director Douglas R. Lowy, MD, will become acting director. Read more.
Sentinel lymph node biopsy may not be necessary for some older women with breast cancer
Similar proportions of older women with node-negative and node-positive early breast cancer had Oncotype Dx breast recurrence scores that would qualify them for adjuvant chemotherapy, according to study results. Read more.
Molecular differences may explain higher breast cancer mortality rates among Black women
Black women are 41% more likely to die of breast cancer than white women, according to American Cancer Society statistics. Read more.
Safety-net hospital sees increase in late-stage breast cancer diagnoses during pandemic
COVID-19 restrictions led to a 1.2-fold increase in presentation of late-stage breast cancer at an urban safety-net hospital, according to a study presented at an American Society of Breast Surgeons Annual Meeting press briefing. Read more.